MA
Microba Life Sciences Limited
MAP.AX · ASX
$0.05 +0.00% (+$0.00)
1M -13.51%
Market Cap $35.1M
P/E Ratio -
Div. Yield -
ROE 67.53%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
84 /100
Cheap P/B 1.44x
P/S 2.38x
EV/EBITDA N/A
Growth
78 /100
Growing Book val. growth 14.18%
Rev. growth 39.64%
FCF growth N/A
Profitability
0 /100
Weak Net margin 140.40%
Op. margin 137.58%
FCF margin 85.45%
Quality
5 /100
Poor ROE 67.53%
ROA 52.05%
Asset turnover 0.37x
Debt
58 /100
Moderate Current ratio 1.24x
Int. coverage -85.11x
Debt/Equity 0.17x
Stability
21 /100
Unstable Rev. volatility 66.58%
EPS volatility 29.69%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MAP.AX
Online
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Luke Reid
Employees
80
Headquarters
Brisbane
Upcoming events
03 MAR
Earnings
Upcoming earnings report